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AN ANALYSIS OF MODIFIABLE RISK FACTORS, GENETIC 
UNDERPINNINGS, AND CURRENT MEDICATIONS FOR ALZHEIMER’S 
DISEASE 
JACK BAILEY 
ABSTRACT 
Alzheimer’s disease (AD) is a widespread neurodegenerative disorder that affects tens of 
millions of patients worldwide. Throughout the last two decades an incredible amount of 
time and resources have been funneled into hopefully finding medications that would 
provide a cure. Unfortunately, no such compound has been identified and instead the only 
FDA approved medications for AD to date target symptomatic management and may not 
even be effective for longer than a couple of years. To this end, this paper sets out to 
identify modifiable risk factors for AD as well as provide recommendations for clinicians 
on how best to utilize the tools currently available to them to treat AD. Additionally this 
paper addresses common flaws in AD clinical trial study designs and provides future 
research directions to expand outside of the popular amyloid hypothesis and instead 
potentially focus on a multi-pathway mechanism of the disease. The following thesis will 
outline several potential mechanisms that can lead to the hallmark pathologies seen in 
AD, primarily amyloid deposition and neurofibrillary tangles as well as neuronal death. 
The majority of commercial and research interest into AD has been focused on the 
amyloid hypothesis and the notion that stopping the formation of amyloid plaques would 
stop the disease course. However, in recent years other mechanisms and neurotoxic 
pathways such as inhibition of tricarboxylic acid (TCA) cycle enzymes, 
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neuroinflammation, and tauopathy have been shown to contribute both to the formation 
of amyloid plaques as well as contributing to AD pathology in their own right. The 
modifiable risk factors explored in this paper include the effects of triglycerides as well 
as intake of antioxidant vitamins and omega-3-fatty acids, both of which are beneficial 
for brain health. This paper will also highlight some of the extensive research on the 
Apolipoprotein E gene and the effects the various alleles have on AD risk. These being 
the putative protective effect of the APOE2 allele, “neutral” effect of the most commonly 
found APOE3 allele, and finally the deleterious effects of the APOE4 allele, believed to 
be the strongest genetic risk factor for late-onset AD.  
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INTRODUCTION 
Alzheimer’s Disease (AD) is a neurodegenerative disease that is believed to affect 
around 47 million patients worldwide and close to 5 million people in the United States 
alone (Khoury, 2018; Thangavel 2017). The disease primarily affects older individuals 
and symptoms are often not seen until after age 65, despite there being strong evidence 
that the cascade of events that define the disease may start decades earlier, especially in 
those at higher genetic risk of developing Alzheimer’s. According to a Centers for 
Disease Control (CDC) Morbidity and Mortality report from May 2017 a total of 93,541 
deaths occurred from Alzheimer’s in 2014, a population adjusted increase of 54.5% from 
1999 (Taylor, 2017). These numbers illustrate just how widespread and destructive 
Alzheimer’s disease is and the fact that the impact of the disease is growing due to a 
number of factors. These factors include an increase in longevity and the fact that AD 
primarily affects older populations. Another reason for the rise of AD deaths is that 
advances in treatment of other widespread conditions in the U.S. such as cardiovascular 
disease and cancer have been made whereas there have been no similar steps taken in the 
treatment of AD. The risk of AD is also increased by other common comorbidities in the 
United States such as alcohol use disorders, unhealthy triglyceride levels and 
cardiovascular conditions such as hypertension (Ihara, 2018; Nagga, 2018; Schwarzinger, 
2018). The economic cost of dementia and AD is huge in the United States and is 
projected to be in the hundreds of millions of dollars each year, with one author even 
stating that in 2018, dementia could become a trillion-dollar disease worldwide 
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(Gonzales-Reyes, 2017). In addition to the devastating toll that Alzheimer’s takes on 
patients and societies in general it also constitutes a significant physical, emotional, 
mental, and financial stress on the loved ones of affected patients. Many times family 
members of Alzheimer’s patients are left to care for their loved ones at home and may 
miss work or have to funnel their own finances into the care and comfort of those with 
Alzheimer’s. The impact on unpaid caretakers and family members may also be 
increasing as evidenced by findings that the number of AD patients that died at home 
increased from 13.9% in 1999 to 24.9% in 2014 (Taylor, 2017). This constitutes a huge 
jump and underlines the damage that AD causes to those closest to patients.  However, 
despite the devastating effects of the disease and the vast resources that have been 
allocated to AD research there is still little progress in finding either a cure or 
consistently reliable biomarkers that could be used to predict the onset of the disease and 
a good start point for treatment.  
CURRENT HYPOTHESIS ON CAUSES OF AD 
 Alzheimer’s Disease is characterized by a buildup of plaques and neuronal death 
due to a deposition of misfolded Aβ proteins, primarily Aβ42 (Aβ42), and 
phosphorylated Tau (p-Tau) proteins, especially p-Tau 181.The current amyloid 
hypothesis states that due to an imbalance between amyloid generation and clearance of 
amyloid from these plaques causes the phosphorylation of tau proteins, which make up 
the characteristic neurofibrillary tangles that are seen in postmortem AD brains.  The 
most common form of AD is the late onset form which affects around 90% or more of the 
AD population (Gonzalez-Reyes, 2017), however there are a few genetically inherited 
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forms that show symptoms and neurological changes much earlier and may account for 
approximately 10% of AD cases, depending on the source. Most of the early onset 
inherited forms of the disease center around defects in the genes for amyloid precursor 
protein (APP), presenilin 1 and 2 (Gonzalez-Reyes, 2017).  
This buildup of Aβ plaques in the brains of affected individuals has been the 
primary target of clinical research and drug development over the last twenty years with 
almost every major pharmaceutical company proposing drugs hoping to reduce amyloid 
deposition. The majority of these drugs have been targeted at the beta and gamma 
secretases, which cleave APP into amyloid fragments that can become neurotoxic. This is 
because although all three secretases (alpha, beta, and gamma) act on APP in healthy 
adults an imbalance and increase in the proportion of APP cleavage by the beta and 
gamma secretases is believed to lead to the neurological symptoms of AD. This increased 
cleaving by beta and gamma secretases leads to a larger development of Aβ42 and Aβ40, 
which in high enough concentrations become neurotoxic. This is because the beta and 
gamma secretases typically cleave the protein in the area that forms Aβ42 or Aβ40. Aβ42 
and Aβ40 have been the two most widely targeted isoforms seeing as these are the most 
commonly implicated in the progression of the disease (Kurz, 2011). Cleavage of APP by 
either beta or gamma secretase leads to the formation of Aβ and the possibility of 
amyloid deposition and therefore drugs targeted at these enzymes have looked to either 
knock them down or inhibit them. A good example of this would be the wide number of 
prospective drugs that have been proposed to inhibit or even completely knockdown β-
site APP cleaving enzyme (BACE1) (Gonzalez-Reyes, 2017).  The gamma secretase 
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enzyme has also been targeted by some studies and companies, but due to the fact that 
this enzyme works as a multi-enzyme complex it has been harder to directly target. In 
contrast to the beta and gamma secretases the alpha secretase actually cleaves the APP 
protein in the middle of the segment that eliminates the generation of neurotoxic Aβ42 
and releases a neuroprotective fragment, sAPPα. For this reason alpha secretase is 
believed to be protective against AD. Therefore research and novel therapeutics aimed at 
alpha secretase have been focused on upregulating and stimulating that enzyme, rather 
than knocking it down or inhibiting it’s activity. 
Zhu and colleagues also found evidence that another protein, dynamin 1, interacts 
and accentuates BACE activity and amyloid genesis (Zhu, 2011). Their work was 
performed in a murine model with a knockdown of the gene encoding dynamin 1 (Dyn 
1). When Dyn 1 was knocked down, production of AB40 was reduced by almost 63% 
and Aβ42 production was reduced by 45%. The authors also found that mice treated with 
dynasore, a selective dynamin inhibitor, had Aβ reduction similar to mice treated with a 
BACE inhibitor (Zhu, 2011). These findings provide evidence of the interaction of other 
proteins with the secretases that act on APP and potentially provide alternative targets to 
the BACE enzyme for researchers and pharmaceutical companies looking to develop 
novel compounds aimed at reducing amyloid deposition. Hopefully dynamin inhibition 
would be tolerable in human patients and could possibly lead to a drug, which could be 
used to slow or reverse AD pathology rather than simply manage clinical symptoms once 
they arise.   
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Intriguingly, strong stimulation of APP, which occurs via APP dimerization, can 
also be dangerous and neurotoxic as shown by a study conducted by Rohn and 
colleagues. Their study used 22C11, an antibody of APP, to stimulate APP and cause cell 
death and degradation in neurons treated with 22C11 (Rohn, 2000). The researchers also 
showed that the mechanism of neurological damage was oxidative stress and damage, 
which is a common occurrence in AD patients. The researchers reached this conclusion 
due to the fact that when neurons were pretreated with GEE, an antioxidant, the 
damaging effects of 22C11 were completely prevented (Rohn, 2000). Oxidative stress 
and neurological damage as alternative pathways to AD will discussed more later in this 
paper as well. Both the damaging effects of 22C11 stimulation on APP and the protective 
effects of GEE were also observed in hippocampal neurons specifically, which is a brain 
region of vital interest in AD seeing as the hippocampus is closely associated with 
memory (Rohn, 2000). The researchers also found that 22C11 damage works by 
activating caspases which in turn, then target specific cytoplasmic proteins.  Once again 
this finding was confirmed by treating cells with a caspase inhibitor and by doing so the 
toxic effects of 22C11 were also completely prevented.  The region of the APP protein 
that 22C11 interacts with is APP66-81, which lies in the cytoplasmic portion of the 
protein. It has also been proposed that APP stimulation may affect downstream cascades 
or interact with G-linked proteins in order to stimulate apoptotic mechanisms (Rohn, 
2000). It has also been shown that APP undergoing apoptosis may be cleaved by caspases 
to create more beta amyloid proteins and therefore lead to a feedforward or positive 
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feedback loop that encourages further amyloid deposition and neurological damage 
(Rohn, 2000).  
There is also experimental evidence to show that pyroglutamate may modify 
Aβ42 to enact different cytotoxic properties and profiles. Gunn and colleagues showed 
that pyroglutamate modified Aβ42 had a higher efficiency of forming dityrosine bonds, 
which can stabilize beta-amyloid plaques and cause a more hydrophobic environment, 
which promotes aggregation (Gunn, 2016). However, contrasting the experimenters’ 
expectations pyroglutamate modified Aβ42 actually decreased reactive oxygen species 
production and could even decrease the production of ROS by non-modified Aβ42, if 
present in high enough concentrations (Gunn, 2016). This finding would suggest a 
potential helpful role of pyroglutamate modified Aβ42, unfortunately the researchers also 
found that this modified amyloid species was harder to clear and at moderate doses also 
made the normal form of Aβ42 harder to clear. Modified Aβ42 also underwent lipid 
peroxidation at a significantly higher rate than non-modified Aβ42, which is concerning 
due to a risk for higher hydrogen peroxide production (Gunn, 2016). All of these findings 
led the researchers to posit that both the non-modified and pyroglutamate modified forms 
of Aβ42 are neurotoxic and play key roles in the development of AD pathogenesis, but 
their exact mechanisms of toxicity may differ. Whereas the non-modified form of Aβ42 
may be responsible for more ROS production the modified species seems to allow 
amyloid aggregation to happen faster, acting as a “seed” for the initiation of deposition 
(Gunn, 2016). Pyroglutamate modified Aβ42 may also be more difficult to clear and 
increase peroxidation. Therefore, Gunn and colleagues’ research furthers the notion that 
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we may need to start approaching AD as a disease that can arise from a variety of 
pathways and treatment should focus on trying to slow the progression on multiple 
different fronts. Their findings also led Gunn to posit that the modified form of Aβ may 
be driving earlier stages of neurodegeneration whereas the non-modified version may 
play a larger role in accelerating and advancing the course of the disease once the 
pathological groundwork has been laid (Gunn, 2016). In fact some researchers have even 
labeled the effects of pyroglutamate modified Aβ as “prion-like”, due to its ability to 
potentially initiate the formation of amyloid plaques in elderly patients (Gunn, 2016).  
Astrocyte damage plays a huge role in the amyloid hypothesis as well, because 
astrocytes can activate different proteases to cleave amyloid residues, many of the 
enzymes activated by astrocytes to help clear Aβ are metalloendopeptidases (Gonzalez-
Reyes, 2017). The APOE4 genotype also has an interaction with astrocyte related 
amyloid clearance because APOE4 transgenic mice have been shown to have a lesser 
astrocyte response and clearance of Aβ in comparison to mice expressing other ApoE 
genotypes. Unfortunately, astrocyte activity can also be detrimental in AD progression 
because there is evidence that points to the possibility that astrocytes may increase the 
production of Aβ in response to neuroinflammation and many of the chemokines and 
cytokines that are released by inflammatory pathways such as the ones triggered by Nf-
kB (Gonzalez-Reyes, 2017). This is because the cytokines TNF-alpha, Interleukin-1beta, 
and others are able to stimulate the beta and gamma secretase enzymes and cleave APP 
into the amyloid monomers that form the characteristic amyloid plaques seen in AD 
(Gonzalez-Reyes, 2017). The fact that astrocytes can also help trigger the release of these 
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same cytokines means that if unchecked neuroinflammation and astrocytes could create a 
positive feed-forward loop, which helps to stimulate Aβ production and aggregation and 
expedite the course of the disease and the onset of clinically relevant symptoms. The 
activation of astrocytes in trying to repair AD related damage has been supported by 
increased levels of MAO-B, an enzyme that is utilized by astrocytes, in post mortem 
brain images of AD afflicted patients (Gonzalez-Reyes). It has also been stipulated that 
L-dyprenyl, an inhibitor of MAO-B, could be used as a biomarker to measure levels of 
astrocytosis and astrocyte response to AD damage in pre-symptomatic patients 
(Gonzalez-Reyes, 2017).  
Neurotransmitter imbalance has also been shown in postmortem AD brains, 
specifically an imbalance in the glutamine-gamma aminobutyric acid (GABA) cycle and 
relationship. This imbalance is due to a larger proportion of GABA being developed 
because of a reduction in pyruvate carboxylation and tricarboxylic acid cycle turnover 
along with a reduced expression of glutamine synthetase (Gonzalez-Reyes, 2017). There 
is biochemical evidence to suggest that amyloid plaques trigger GABA production and 
release from astrocytes. The studies on GABA and AD have also shown that the 
complete suppression of GABA release can reverse the cognitive deficits and the 
impairments in neuroplasticity that were observed under increased GABA production 
(Gonzalez-Reyes, 2017). Therefore, these studies pave the way for another class of 
potential therapeutics in combatting AD development, and a potential drug class that may 
actually help to reverse or halt the disease progression as opposed to the current FDA 
approved medications, which only seek to alleviate symptoms.  
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A third area of research into causative factors for AD, and the hopeful 
development of novel therapeutics aimed at AD, is the role that reactive oxygen species 
and neuroinflammation play in the development of (or protection against) AD. Several 
labs have compiled evidence that neuroinflammation is a reaction to Aβ deposition and 
that astrocytes in the brain may play a key role in the further development of AD from 
earlier prodromal stages into a clinically manifested form. Gonzalez-Reyes and 
colleagues in a published literature review propose that the NF-kB pathway, which can 
cause both proinflammatory and anti-inflammatory cascades, may be a critical player in 
how neuroinflammation affects brain health and AD by being a “switch” between 
protective and neurotoxic consequences (Gonzalez-Reyes, 2017). Gonzalez-Reyes et. al. 
started their review by discussing how Aβ deposition can interfere with astrocyte 
signaling and communication leading to a pattern of neurotoxic excitatory firing signals 
(Gonzalez-Reyes, 2017). This thought is further evidenced by the fact that drugs, which 
inhibit the NMDA receptors can help alleviate Aβ-induced synaptic damage and 
dysfunction in the hippocampus (Gonzalez-Reyes, 2017). Thangavel et. al. found that 
glial maturation factor (GMF) was increased in astrocytes around amyloid plaques on 
assays of immunofluorescence, and that this was linked to the APOE4 allele, providing a 
possible mechanistic insight into how APOE4 may contribute to AD pathogenesis 
(Thangavel, 2017). The authors postulate then that GMF may play a role in the 
neuroinflammation seen in AD and may attenuate the relationship between APOE4 
genotype and Aβ accumulation and deposition (Thangavel, 2017). However, this is an 
important finding because it gives researchers, pharmaceutical companies, and clinicians 
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a potential target and pathway to attempt to develop drugs and novel therapies for in the 
largest group of at risk AD patients, APOE4 carriers.   
 The transcription factor NF-kB has been implicated in the toxic 
neuroinflammatory responses seen in AD, due to its ability to stimulate the release of 
various cytokines downstream after it’s activation and crosstalk with other inflammatory 
pathways and signals. The NF-kB pathway can also be stimulated by reactive oxygen 
species (ROS), often generated by mitochondrial dysfunction (Gonzalez-Reyes, 2017). 
However, the NF-kB pathway and factor also serves an important normal physiological 
function and therefore any novel therapeutics or drugs aimed at it would have to be 
specific and aim to achieve a partial inhibition or perhaps knockdown rather than total 
suppression or complete knockout.  
 An alternative to the amyloid hypothesis for the development of AD is one that 
focused around mitochondrial dysfunction. This hypothesis states that mitochondrial 
dysfunction and demand for cellular energy may underlie some of the neurological 
hallmarks of AD either in cooperation with the amyloid hypothesis or independent of it. 
One strong area of support for this notion is the fact that lower levels of brain glucose 
metabolism are often seen in AD patients and, as mentioned above, the formation of 
reactive oxygen species and oxidative stressors that arise from mitochondrial dysfunction 
may damage parts of the brain and help to trigger neuroinflammatory cascades which, in 
turn may trigger amyloid deposition or increase the rate of deposition. One very 
important mitochondrial pathway that is severely affected in AD and by the inflammatory 
cascades seen in the development of AD is the citric acid cycle, in which vital enzymes 
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are inhibited. This inhibition to the cycle produces less electron carriers as well as 
glucose than normal (Gonzalez-Reyes, 2017). It should also be remembered that the citric 
acid cycle can be used to create products that can feed into glycogen synthesis, fatty acid 
metabolism, nucleic acid synthesis, and several other key pathways for mitochondrial 
health and so by disrupting this cycle it has widespread implications for several areas of 
cellular health outside of simple glucose metabolism. In addition to disruptions in the 
TCA cycle, some researchers believe that the neuropathology of AD may also affect the 
electron transport chain and the carriers within this pathway. If this is true, then it is 
important to remember that the complexes involved in the electron transport chain lie on 
the inner mitochondrial membrane, and therefore membrane health and phospholipids are 
integrally tied to the physical location of the chain, and secondly that the transport chain 
is the largest source of glucose synthesis in cellular respiration.  In fact the triggering of 
inflammatory cascades and the release of reactive oxygen species is the mechanism by 
which Vinceti and colleagues proposed that the neurotoxic selenium species they 
discovered may be acting in order to increase the risk for neurodegenerative diseases 
such as AD (Vinceti, 2017).  
 The above review of possible pathways that may lead to AD brings several issues 
to the forefront of the debate on AD such as the need for a comprehensive and sensitive 
biomarker profile in order to identify if AD is developing in a patient before clinical 
symptoms present, a wider array of therapeutics including those that may actually slow 
the course of the disease or cure it rather compounds for symptom management. 
Currently several plasma or cerebrospinal fluid (CSF) species can be used as biomarkers 
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for the development and progression of AD, these include CSF Aβ40 and Aβ42 levels, 
and CSF phosphorylated tau. In addition, several imaging techniques such as Pittsburgh 
Compound B (PiB)-Amyloid imaging and 18F imaging can be used to detect tau 
phosphorylation (Byun, 2017; Johnson, 2017; Nagga, 2018). Furthermore, the importance 
and impact of genetic medicine and incorporating patients’ genotypes into clinical 
decisions has become apparent with AD since information on alleles and which patients 
may be carriers for deleterious and damaging alleles, such as the E4 allele for APOE 
genotype, or risky alleles in macrophage and microglial networks, will inform physicians 
on which courses of treatment would be most likely to show the most benefit and effect 
in an individual patient (Spinney, 2014; Tansey 2018).  
 
GENETIC RISK FACTORS FOR AD  
 Many genes have been implicated in at least having a role in the development of 
Alzheimer’s but, Apolipoprotein E has been shown to be the most common and strongest 
risk factor gene for sporadic AD (Gonzalez-Reyes, 2017, Yassine, 2017; Zhu, 2015).  
 The normal biological function of apolipoprotein E is in cholesterol transport and 
therefore the protein is essential and serves a vital physiological function. APOE is also 
found in several organs outside of the brain and therefore much of the research on APOE 
has been focused on better understanding why certain alleles, namely the APOE4 allele, 
confer a higher risk to Alzheimer’s in order to develop more selective targets or proteins 
of interest (Altmann, 2014).  APOE has three natural alleles in humans APOE2, APOE3, 
and APOE4. Research has shown support for the notion that APOE4 is a damaging allele, 
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APOE3 seems to be “neutral” and APOE2 may even convey a protective advantage 
against the onset of Alzheimer’s (Suri, 2013). Several studies have reported that a person 
heterozygous for APOE4 has between a three and four times greater risk of developing 
AD than a person homozygous for APOE3 and that someone who is homozygous for the 
APOE4 allele may face up to a twelve-fold increase in their risk for AD (Spinney, 2014). 
Though the discovery of the APOE gene in connection with AD is not a brand new one 
researchers have been unable to elucidate the mechanisms for how the different alleles 
either protect against or convey a higher risk for Alzheimer’s. In a literature review on 
the APOE gene, Spinney mentions two possible mechanisms by which APOE is linked to 
Alzheimer’s. The first is amyloid dependent and states that APOE4 promotes amyloid 
deposition in the brain, which leads to and is one of the hallmarks of AD, whereas 
APOE2 actually works to decrease amyloid buildup (Spinney, 2014). The second 
proposed mechanism is not linked to amyloid buildup and instead posits that stressed 
neurons make APOE as part of their repair mechanism and deleterious or damaged 
APOE4 is broken down into fragments that are cytotoxic and may damage brain cells’ 
mitochondria and cell skeletons (Spinney, 2014). Earlier work by Zhu and colleagues 
found that the phosphoinositol metabolites, PI and PIP2, were decreased in APOE4 
carriers as compared to APOE3 subjects and that PIP was increased in APOE4 subjects 
(Zhu, 2015). These findings were observed along with progression from normal aging to 
mild cognitive impairment (MCI) to AD in the human cortex tissues that were employed 
in this experiment. The reduction in PIP2 also relates back to the amyloid hypothesis of 
APOE4 seeing as PIP2 reduction has been implicated in exacerbating amyloid deposition 
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and burden (Zhu, 2013). This relation between PIP2 and APOE4 genotype was also seen 
in a murine model. The study also found elevated levels of synaptojanin 1, a protein that 
serves to degrade brain PIP2, thereby giving evidence for a mechanism by which the 
phosphoinositol degrading hypothesis could be carried out. It was found that cognitive 
decline can be rescued and PIP2 can be restored if levels of synaptojanin 1 can be 
reduced. This fact that the damaging effects of synaptojanin 1 can be reversed is strong 
evidence that synaptojanin 1 is directly related to cognitive effects (Zhu, 2013 and 2015).  
 Conversely APOE2 has been shown to enhance longevity and decrease AD 
neuropathology and cognitive decline, however APOE2 is also the rarest allele and form 
of the APOE gene with only 8% of the general population possessing a copy of the allele 
(Spinney, 2014). Suri and colleagues found that APOE2 carriers have less amyloid 
plaques and neurofibrillary tangles than carriers of the E3 or E4 alleles. Suri proposes 
that a cysteine-arginine single substitution in APOE2 causes it to be more stable and 
resistant to denaturation and this may be part of the reason why the APOE2 allele confers 
a protective advantage to the neuropathological hallmarks of AD (Suri, 2013). The 
authors also propose that a positive amino acid at position 112, instead of the negative 
cysteine found in APOE2 and APOE3 proteins, allows APOE4 greater domain 
interactions and this difference in charge and conformation may lead to the negative 
effects seen in APOE4 subjects (Suri, 2013). In mice it has also been shown that APOE2 
mice are more efficient at clearing Aβ residues from the bloodstream and degrading them 
than APOE4 mice, this gives further clarity to the mechanisms by which APOE2 slows 
the progression of AD (Suri, 2014).  
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 It is clear from the literature and prior research into genetic underpinnings of 
Alzheimer’s disease that the APOE gene and its alleles play a key role in either 
expediting or retarding the development of the neurodegenerative disease, however there 
is also evidence to imply that APOE4 allele may confer a higher risk depending on 
biological sex because research shows that APOE4 carrying females are at the highest 
risk for both AD development along with worse symptom profiles and faster symptom 
onset (Altmann, 2014). Some papers and researchers have even estimated that women 
who carry just one copy of the APOE4 allele are at four times greater risk for AD than 
women who are homozygous for APOE3. Altmann and colleagues performed a 
retrospective cohort study to further examine the APOE-biological sex interaction and 
found that the rate of clinical conversion from normal aging or mild cognitive impairment 
(MCI) to AD was significant for APOE4 by sex interaction resulting in a 1.8 fold risk of 
clinical conversion over AD in older women (Altmann, 2014). There was not a 
significant increase in risk for men carrying the APOE4 allele. Altmann did not find a 
change in Aβ levels of APOE4 women and therefore hypothesized that the mechanism by 
which the interaction occurs must be downstream of Aβ pathology. This hypothesis is 
reasonable given that Aβ deposition is typically viewed as an early step in the progression 
and onset of the AD. It should also be noted that other cerebrospinal fluid (CSF) 
biomarkers, like tau levels, were also found to be non-significant for the genotype by 
female sex interaction (Altmann, 2014).  
 Perhaps the most exciting recent development in AD research is the finding of the 
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) gene link to AD risk for 
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those that carry the R47H mutation in the TREM2 gene. TREM2 plays a role in amyloid 
uptake and compaction and therefore haplodeficiency of the gene leads to a higher risk 
for AD with an odds ratio ranging from 2.9 to 4.5 higher risk (Yeh, 2016). Homozygous 
loss of function mutations in the TREM2 genotype leads to another devastating 
neurological disorder, Nasu-Hokola disease, which is often characterized by bone cysts, 
neurodegeneration and loss of white matter earlier in life, typically around the fourth 
decade. (Yeh, 2016) The arginine to histidine point mutation at position 47 has been 
classified as a loss of function mutation and is believed to confer a higher risk of AD 
because the presence of arginine leads to key structural changes in the CDR2 ligand. This 
interrupts the binding loop including causing the histidine at position 67 to swing 180 
degrees towards the CDR1 region of the protein and H47, rather than extend towards the 
exterior of the protein, in the three dimensional structure seen with the wild type 
genotype (Sudom, 2018). This change in conformation is even more important when 
taken in conjunction with the findings of Yeh and colleagues which demonstrated 
TREM2 binds to the apolipoproteins of APOE and CLU/J which can coordinate and bind 
amyloid-beta and thereby this conformational change in one of the binding pockets in the 
R47H mutation of TREM2 may directly lower the ability to bind and clear amyloid 
plaques (Yeh, 2016). Wang et. al. conducted examined TREM2’s effect on microglia to 
uptake Aβ and once again found that TREM2 is necessary for reactive microgliosis and 
that the R47H mutation confers a lower ability to uptake Aβ plaques and therefore 
TREM2 genotype does modulate amyloid-beta accumulation (Wang, 2015). Studies by 
Yuan offered another possible explanation for TREM2’s role in Alzheimer’s and plaque 
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management and that was that TREM2 facilitates microglia’s ability to form a protective 
barrier around plaques. TREM2’s contact with plaques and amyloid deposits makes them 
less well contained and this could be a second neuropathological basis for the R47H 
mutation in TREM2 (Yuan, 2017). Furthermore, Cheng and colleagues showed that the 
negative effects of the R47H mutation can be alleviated in mice with the use of TREM2 
activating antibodies (Cheng, 2018). This finding adds more support to a direct link 
between the R47H loss of function mutation and AD risk, but also provides a potential 
therapeutic avenue for those patients at risk of AD development due to presenting with 
the R47H mutation. Cheng also found that bone marrow derived macrophages with the 
R47H mutation had smaller cell survival due to increases in apoptotic and necrotic 
events. When cells were treated with a commercially available TREM2 specific antibody 
cell proliferation, migration, and survival was increased in the wild type and R47H mice, 
but not in knockout mice (Cheng, 2018).  
Tansey and colleagues conducted a study of locations of genes implicated in AD 
and found that many of the genes that are associated with AD risk code for macrophages 
or microglia, both immune system cells (Tansey, 2018). Interestingly one of the enriched 
motifs they found for their macrophage studies included the gene for transcription factor 
NF-kB, which has been reviewed extensively elsewhere and could be a key “switch” in 
the neuroinflammation and damages seen in AD patients (Gonzalez-Reyes, 2017; Tansey, 
2018). This study is helpful to the current field of AD research by highlighting more 
genes that could be screened for and evaluated on genotypes of patients in an effort to 
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better parse out which patients a clinician might have to follow closer than others in 
terms of their potential risk for AD.  
 
MODIFIABLE RISK FACTORS FOR AD 
Due to the devastating effects that Alzheimer’s disease presents on both a 
personal and societal level countless studies have been done in order to help illuminate 
risk factors and their connection to AD in order to help better educate the public. Among 
the various risk factors that have been implicated in the literature are alcohol use, higher 
levels of triglycerides and dietary lipids, and comorbidity with vascular diseases (de 
Wilde, 2017; Ihara, 2018; Nagga, 2018; Scwharzinger; 2018). 
Nagga et. al. found that participants who showed higher levels of triglycerides in 
midlife were also more likely to show abnormal levels of Aβ42 on imaging scans twenty 
years later in addition to an abnormal Aβ42/p-tau ratio (Nagga 2018). Even more 
importantly this finding was independent of APOE4 status, sex, age, and vascular risk 
factors meaning that the risk of triglycerides for AD is not purely associated with APOE 
genotype or an underlying vascular diagnosis and instead seems to be a pertinent and 
significant risk factor in its own right (Nagga, 2018).  
The findings of Nagga were backed up by a larger study looking at the members 
of the Wisconsin Registry for Alzheimer’s Prevention (WRAP) participant pool and the 
authors found that both getting enough sleep and a healthier metabolic and cardiovascular 
fitness profile had protective effects on cerebral blood flow, grey matter concentration 
and episodic memory performance (Johnson, 2017). The study goes on to state that 
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previous studies have found physical activity to preserve brain volume in several key 
areas and that some researchers believe that physical activity may be the modifiable risk 
factor with the highest effect on reducing AD (Johnson, 2017). These findings go hand in 
hand with the findings of the Nagga study, which state that higher triglycerides confer a 
greater risk to AD (Nagga, 2018). The WRAP study also was able to identify that much 
of the effect of parental history of AD was actually attributable to having a copy of the 
APOE4 allele and further provided evidence that clinical biomarkers can be reliable 
estimates of disease progression before clinical symptoms even present (Johnson, 2017).  
 Nutritional status and diet can be a risk factor for AD. Wilde and colleagues 
conducted a meta-analysis of studies looking at key nutritional species and their relation 
to Alzheimer’s risk. In terms of levels of nutrients in systemic circulation they found that 
plasma levels of the lipids docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), 
and phosphatidylcholine (PC) were significantly lower in AD patients than in a group of 
healthy elderly controls, they also found that selenium was significantly lower. However, 
it should be noted that the selenium species picked up in these analyses may differ from 
the inorganic neurotoxic selenium species discussed by Vicente (de Wilde, 2017). 
Vicente et al also failed to detect a significant difference for brain selenium species in 
their analysis, but did find significantly lower levels of CSF DHA, brain choline 
containing lipids, CSF folate, CSF vitamin B12, CSF vitamin C, CSF vitamin E, and 
brain zinc (de Wilde, 2017). The lower brain choline containing lipids could cause 
problems with neuroplasticity or neuronal membrane disturbances.  Lower CSF vitamin 
C may be an indicator of weakened immune status or lower antioxidants. DHA and EPA 
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are both omega-3-fatty acids that can be ingested from eating fish or fish oil and have 
been found to be vital for brain health and both have also been found to help lower 
triglycerides (de Wilde, 2017). When viewing these data alongside the findings of Nagga 
et. al. the lowered plasma and CSF findings of DHA and EPA could be especially 
dangerous because Nagga and colleagues found that higher levels of triglycerides can be 
a risk factor for pathological Aβ42 deposition in individuals and therefore should be 
considered a risk factor for neurodegeneration and AD (Nagga, 2018). The authors 
hypothesize that lower blood and CSF levels of these nutrients are the result of lower 
intake due to dietary choices, including the fact that diets like the Mediterranean diet are 
higher in omega-3-fatty acids and antioxidants than many traditional western diets. 
Therefore it is possible that the Mediterranean diet may have some beneficial effect on 
AD risk, though this hasn’t been readily proven yet.  The findings on dietary choices 
once again support the notion that healthy lifestyle and diet choices, such as lower 
triglycerides, and higher intake of vitamins may be a key risk factor in the development 
of late onset AD as well as having the benefit of being easily modifiable, unlike many of 
the other risk factors for AD. The data on diet underlies the importance of lipid species in 
the development of AD because lipids are necessary for brain health and the maintenance 
of a healthy phospholipid bilayer in brain cells. Many traditional Western diets are high 
in unnecessary triglycerides and therefore should be replaced with more advantageous 
dietary solutions such as the Mediterranean diet and intake of omega-3 fatty acids, such 
as EPA and DHA, from food sources such as fish or fish oil supplements.  
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Soininen et. al. conducted a randomized study on the effects of one clinically 
created diet to combat the worsening symptoms of AD, Souvenaid, in an effort to better 
understand if long-term adherence to diets specifically engineered for AD had significant 
health benefits for patients.  The active component of Souvenaid is a combination of 
DHA, EPA, uridine monophosphate, choline, B vitamins (B12, B6), Vitamin C, vitamin 
E, folic acids, phospholipids, and selenium (Soininen, 2017). This artificial diet focuses 
on many of the nutritional components that have been linked to AD, such as lower DHA, 
EPA and phospholipid levels. It is also interesting to note that many of the ingredients in 
the active combination of Souvenaid are species that de Wilde and colleagues screened 
for and found lower plasma or CSF levels of in their AD patients, therefore other research 
in the field is certainly supporting the makeup of Souvenaid (de Wilde, 2017; Soininen, 
2017). The hope was that by providing patients with these species exogenously the 
neurodegenerative and cognitive insults of AD may be slowed seeing as the patient 
would now have ample building blocks to help repair or restore damaged neurons or 
phospholipid bilayers. Vitamin C has been well established benefits for immune health 
and warding off infection and so could have been included in the diet in order to help 
combat opportunistic diseases, an important benefit in elderly populations. The most 
interesting ingredient included in Souvenaid though is selenium. Based on the findings of 
Vinceti, which showed that some inorganic selenium species can be neurotoxic, it would 
be helpful to know what the dosage of selenium is in Souvenaid and if the form included 
in Souvenaid could be metabolized to Se (VI), the most neurotoxic species found by 
Vinceti (Vinceti, 2017). Perhaps, future studies could evaluate any difference between 
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patients taking Souvenaid with selenium and Souvenaid without selenium to see if there 
is a notable difference in either cognitive performance or neuropathology. However, the 
researchers failed to find a significant difference between subjects who were given 
Souvenaid for 24 months and controls on performance on a neuropsychological test 
battery (NTB). The NTB included measures of immediate word recall, delayed word 
recall, word cognition, category fluency, and digit substitution (Soininen, 2017). 
However, the researchers did find a statistically significant decrease in clinical dementia 
as rated by a sum of boxes calculation, for the active group, such that worsening on 
clinical dementia rating was 45% less in the Souvenaid group compared with the controls 
(Soininen, 2017). This was paired with a finding that hippocampal volume reduction and 
ventricular volume increase was also reduced in the Souvenaid group, providing evidence 
that the diet did indeed slow neuropathology rather than simply retard subjective 
cognitive decline (Soininen, 2017). Adherence to the diet was reported as high, mean of 
93.4% adherence for both groups, and was confirmed by significant increases in plasma 
DHA and EPA in the Souvenaid subjects whereas no such increase was seen in controls. 
The incidence of adverse effects was similar between the two groups and any adverse 
effects were found to be unrelated to the study and dropout was found to not significantly 
affect the study’s findings (Soininen, 2017).  Soininen and colleagues had mentioned that 
earlier trials on Souvenaid had found some statistically supported benefits of the diet, but 
these studies were much shorter in duration and therefore that is why they chose a longer 
timeframe for their study. Overall, their data and study seem to confirm some 
neuropathological protective effect for the Souvenaid diet, but this protective effect did 
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not slow or change subjective perceptions of cognitive performance on a battery of 
memory tests (Soininen, 2017). However, this study was performed in an elderly subject 
population with a mean age of 71 years old. Since it is known that AD symptoms are first 
evident potentially decades after the onset of neurophysiological changes, it is possible 
that changes in cognitive performance may have been difficult to detect due to the 
severity of the neurological changes that preceded the study (Soininen, 2017). An 
interesting next step for this line of research would be to identify a subject pool who is at 
risk for AD, either by using familial history of AD, or genotyping to look for risk genes, 
such as APOE4 and others, and then to perform a long-term randomized study in these 
subjects starting at an earlier age in order to identify if Souvenaid is helpful in slowing 
the earlier stages of neurodegeneration. If this was found to be the case, than Souvenaid 
could be used as a protective measure to help slow the onset of AD, rather than a 
treatment after symptoms have already begun showing.  
Cansev and colleagues were interested in the role that antioxidants play in 
combination with important dietary species for brain health, omega-3-fatty acids and 
uridine. To this end they designed a study to look at the effects of either a low or high 
antioxidant diet and the interaction of antioxidants with DHA, EPA, and uridine (Cansev, 
2017). To test their hypotheses they developed four experimental diets, one that was 
devoid of DHA, EPA and uridine, and low in antioxidants, a second that was low in 
antioxidants but contained DHA, EPA, and uridine, and then two high antioxidant diets, 
again one lacking DHA, EPA, and uridine and one containing these necessary dietary 
supplements (Cansev, 2017). The antioxidants used in the study were vitamin C, vitamin 
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E, and selenium. Cansev et. al found several important differences after feeding their 
diets to a group of rats for six weeks. The level of total brain phospholipids was increased 
by 25% in the rats fed the antioxidant high diet containing EPA, DHA, and uridine 
(Cansev, 2017). There was no significant difference in total brain phospholipids in any of 
the other three diets, including the low antioxidant diet that contained the same level of 
omega-3-fatty acids. Specifically levels of phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine, and sphingomyelin were significantly 
higher in the high antioxidant and dietary supplement diet (Cansev, 2017). Therefore it is 
clear that several vital building blocks of healthy neurons and cell membranes were 
increased in the rats that were fed the high antioxidant and omega-3-fatty acid enriched 
diet. Interestingly these lipid species were only found to be increased in the diet that 
included antioxidants and not the low antioxidant diet that contained the same 
phospholipid species indicating that the presence of antioxidants is necessary for an 
increased uptake of these necessary dietary species (Cansev, 2017). This same 
relationship was also found in levels of both presynaptic and postsynaptic enzymes. The 
pre-synaptic enzyme synapsin-1 was found to be increased by 36.6% in rats fed the 
antioxidant high and dietary supplement diet, as well as having 32.9% higher levels of 
PSD95, a post synaptic enzyme, than the other three diets (Cansev, 2017). Finally, the 
combined antioxidant and omega-3-fatty acid diet also led to increased levels of the 
Kennedy pathway enzymes PCYT1A and CEPT1 in experimental rats (Cansev, 2017). 
The Kennedy pathway is responsible for generating phosphatidylcholine and 
phosphatidylethanolamine in humans, both of which are important building blocks of 
25 
 
healthy phospholipid membranes. Therefore, the data from Cansev’s study show that 
appropriate and adequate levels of antioxidants are necessary for many of the beneficial 
effects of increased dietary DHA and EPA intake (Cansev, 2017). Furthermore, the 
authors go on to propose that antioxidants are necessary to either slow the breakdown of 
neurons and membranes or aid the synthesis of new neuronal membranes or potentially 
aid in both processes. These effects may act through a variety of different mechanisms 
such as preventing lipid peroxidation, stimulating Kennedy pathway enzymes or directly 
acting upon neuronal membranes.  
To further complicate the puzzle of utilizing dietary supplements in an effort to 
stymie AD progression and slow neurodegeneration there is conflicting evidence on 
whether APOE genotype, and specially the APOE4 allele, effects DHA metabolism. In a 
literature review of a number of studies assessing the interaction between APOE 
genotype and DHA metabolism and effects of DHA supplementation it was argued that 
an APOE genotype may interact with DHA metabolism in a variety of methods (Yassine, 
2017). Yassine also argued that studies that have found little effect of APOE genotype on 
DHA intake and effectiveness may be limited by small sample size, using patients 
already far into the progression of AD and thereby less sensitive to changes, and other 
methodological differences (Yassine, 2017). It is also interesting to note that based on the 
findings of Cansev and colleagues, if a study failed to include antioxidants or assess for 
adequate levels of antioxidants in patients than the effects of DHA supplementation may 
be mitigated by antioxidant status (Cansev, 2017). Six randomized clinical trials have 
been found to find a benefit of DHA supplementation on episodic memory, whereas six 
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have not (Yassine, 2017). Yassine and colleagues continue to provide background 
evidence on several factors that may cause DHA and APOE4 interaction. The first of 
these is that APOE4 is more likely to bind the very low density lipoprotein, which is 
catabolized faster in the liver, than its APOE3 counterpart, which tends to bind to HDL 
(Yassine, 2017). This would mean that less DHA survives the “first pass” of the liver 
before it even reaches the brain in APOE4 carriers and therefore higher DHA 
supplementation may be necessary in these patients. This idea is supported by a study 
from Chouinard-Watkins and colleagues that found levels of plasma DHA were 31% 
lower after administration of a single dose of DHA as compared to subjects who did not 
possess a copy of the APOE4 allele. (Yassine, 2017; Chouiinard-Watkins). The second 
mechanism proposed by Yassine and colleagues is that the degradation of the blood-brain 
barrier in APOE4 carriers may allow for lower DHA uptake seeing as a superfamily 
transporter is involved in both DHA uptake and blood brain barrier integrity, Major 
Facilitator Superfamily domain containing protein 2 (MFSD2a) (Yassine, 2017). It is also 
believed that APOE4 proteins carry fewer lipids than APOE3 or APOE2 proteins and 
therefore APOE4 carriers may simply be “harvesting” less DHA from the supplements 
than their counterparts. A fourth mechanism could be that amyloid genesis causes the 
activation of calcium dependent phospholipases, which may degrade DHA (Yassine, 
2017). Therefore, if these enzymes are active at higher levels in APOE4 carriers than 
APOE3 or APOE2 subjects than DHA may be degraded at a faster rate and consequently 
be less available for cells to use to rebuild their neuronal membranes. All of these 
findings underline the potential need for different dosages or delivery mechanisms of 
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DHA for patients who are APOE4 carriers. Yassine and colleagues also suggest 
designing a clinical trial to better understand the interaction of the APOE4 genotype and 
DHA supplementation (Yassine, 2017). Such a study might help to shed more light on 
proper recommendations for omega-3-fatty acid intake based on genotype. Another 
interesting future research direction based off the writings of Yassine would be to 
investigate whether the pathways of DHA uptake are specific to DHA or are 
generalizable to other omega-3-fatty acids such as EPA. Furthermore, Yassine and 
colleagues believe that DHA supplementation and intervention may be most effective, 
and perhaps only effective, during the early prodromal stages of the disease, suggesting 
that after neurodegeneration has progressed, dietary supplementation is unlikely to have 
much effect as it is a preventative and not a curative measure (Yassine, 2017). The 
necessity to provide DHA in the earlier stages of the AD course is due to the fact that 
dietary supplementation, and many of the current interventions for AD, are useful in 
slowing the progression of AD, but may not be able to reverse decades-worth of damage 
once AD symptoms begin to show or later in a person’s life (Cansev, 2018; Nagga, 
2018). This would also state to reason that dietary changes, though helpful at any point, 
may exert the most benefit if instituted earlier in the disease course rather than later. 
Ihara et. al. highlight another critical risk factor for AD, which is cardiovascular 
health, and specifically atrial fibrillation (AF). One of the central tenants of their 
argument is that it is well known that in AD patients the brain is often hypoperfused, 
which can lead to axonal and neuronal damage and working memory impairment, and 
atrial fibrillation could exacerbate any cerebral hypoperfusion that was already present or 
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cause cerebral hypoperfusion in an elderly patient (Ihara, 2018). It should also be noted 
that AF is a strong risk factor for stroke, and earlier research has shown a positive 
correlation between AD and stroke (Ihara, 2018). However, in looking at data from 
studies that differentiate between permanent and non-permanent AF it has become more 
clear that permanent AF may be the more pertinent risk factor. However, many of these 
hypothesis and arguments have not been shown in pathological findings of post mortem 
AD patients. Ihara attributes this difference to a possible under-diagnosing of AF in 
populations and also a large increase in AD as age progresses, which may hide any 
interaction or risk effect of AF in elderly patients (Ihara, 2018). Ihara and colleagues also 
provide results and support from a recent study with patients receiving warfarin as well as 
patients receiving non-vitamin K oral anticoagulants and in both studies medication was 
shown to reduce the risk of new onset dementia, however non-vitamin K oral 
anticoagulants were found to be superior to warfarin (Ihara, 2018). This information 
could be beneficial to clinicians when deciding which anticoagulants to prescribe to a 
patient that may have cardiovascular issues combined with a risk profile for AD or 
vascular related dementia.  
 Buckley and colleagues in a cohort of Australian seniors found that increased 
scores of subjective cognitive decline were associated with age and a higher score on 
global depression scale, but not with sex or years of education (Buckley, 2017). More 
interestingly they found that greater tau deposition in the entorhinal cortex was also 
significantly associated with greater scores of cognitive decline (Buckley, 2017). This 
finding was not seen between tau deposition in the inferior temporal cortex and 
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subjective cognitive decline (SCD). However, greater Aβ deposition was also found to 
associated with greater SCD, but the tau deposition in the entorhinal cortex explained 
more of the variance than any other factor, 47% (Buckley, 2017). They also failed to find 
evidence of an interactive effect between tau deposition and Aβ deposition. When Aβ 
deposition was added to Buckley’s model of factors to predict SCD it was no better than 
simply relying on entorhinal tau deposition alone (Buckley, 2017). The authors argue that 
this tauopathy may precede significant Abeta deposition and may be one of the first steps 
in the long cascade of neurological hallmarks and deterioration seen in AD (Buckley, 
2017). These findings are further supported by a trial performed by Rhodius-Meester in 
which CSF p-tau was found to be a part of their model of predictive factors for mortality 
in AD, but amyloid species, such as Aβ42, were not found to be significant drivers in 
their model (Rhodius-Meester, 2018). The other factors that were found to be significant 
in the Rhodius-Meester model were older age, male sex, worse performance on cognitive 
tests relating to executive function and mental attention or speed (digit span backwards 
and trail-making test A respectively), as well as global and hippocampal specific atrophy 
(Rhodius-Meester, 2018).  
Alcohol is another risk factor for AD and in a study conducted in outpatients from 
French hospitals by Schwarzinger. The authors of this paper went so far as to assert that 
they believe alcohol abuse and use disorders, and not diet or triglycerides, were the 
highest modifiable risk factor for AD in both men and women (Schwarzinger, 2018). 
Alcohol use disorders were recorded in 16% of men with AD, but only 6% of all men in 
their study. In fact they summarized that alcohol use disorders were highly associated 
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with risk for any form of dementia (AD, vascular, or other forms of dementia) and these 
associations persisted after statistical corrections and accounting for other pertinent risk 
factors (Schwarzinger, 2018). These findings and data also fall into the category of 
dietary intake and how dietary choices can affect AD risk given that alcohol use is a 
modifiable risk factor. Furthermore, these findings should underscore the importance for 
seeking therapy and help for anyone affected by an alcohol use disorder given the 
correlation between alcohol use disorders and long-term cognitive and neurological 
health. A limitation of this study though is that it was only looking at the association 
between diagnosed alcohol use disorders and diagnosed dementia and AD cases. 
However, they did not look at the effect of absolute or relative alcohol consumption and 
in many countries substance use disorders may be underreported or under diagnosed due 
to social stigma surrounding seeking clinical help for a substance use disorder.  
A study by Vinceti and colleagues found that an inorganic selenium species, 
many of which are known to be neurotoxic, could be another risk factor for the 
development of AD (Vinceti, 2017). Specifically the study names Se (VI) as the strongest 
risk factor and the selenium species with the highest direct relationship to the 
development of AD in their sample. Additionally, Vinceti found that Se-Methionine and 
Se-HSA may confer a risk for AD as well, albeit a much smaller one than the inorganic 
Se (VI) species (Vinceti, 2017). The authors hypothesized that this specific Se species 
may be linked to either pro-oxidant behavior or protein misfolding seeing as radical 
oxygen species (ROS) have been linked to AD and the amyloid hypothesis is focused 
around the concept of amyloid misfolding and aggregation, which then initiates tau 
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hyperphosphorylation and tangles (Vinceti, 2017). These findings also provide another 
potential biomarker or species for clinicians to monitor in the hopes of identifying AD or 
at a minimum risk factors before symptoms present so the disease progression can be 
slowed or even perhaps halted.  
Research performed in the WRAP subject pool also found evidence for sleep 
having a neuroprotective effect on AD and helping to improve cerebral blood flow, grey 
matter volume and cognitive benefits on episodic memory (Johnson, 2017). Therefore yet 
another area for clinicians to monitor their patients on is sleep and stressing getting the 
most sleep possible. This notion and finding is logical seeing as sleep is a key time in the 
circadian rhythm for the body, the brain included, to perform repairs and maintain a 
healthy state.   
REVIEW OF CURRENTLY FDA APPROVED MEDICATION FOR AD 
Another piece to the Alzheimer’s puzzle is the effect that currently approved 
medications have on patients and their symptoms. As of now there are five medications 
that have been granted FDA approval for the treatment of AD, all of which are used for 
symptom management and none of which have been shown to have curative effects or 
reverse the hallmark neuropathology of the disease. Three of these five medications are 
cholinesterase inhibitors (donepezil, galantamine, rivastigmine). The fourth is a N-
methyl-D-aspartate (NMDA) receptor antagonist, memantine, and the fifth is a 
combination of donepezil and memantine. (Gonzalez-Reyes, 2017). Overall, these drugs 
have a relatively mild adverse side effect profile and positive safety profile. The major 
adverse side effect and complaint with the cholinesterase inhibitors are GI-related distress 
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including vomiting, diarrhea, and nausea, many of which may abate after a steady dose 
has been established and adhered to for a period of time (Chase, 2017; Khoury, 2018; 
Nakamura, 2014). However, almost all of the randomized clinical control trials excluded 
patients who may be on medications for other severe medical conditions or 
comorbidities, and this does not necessarily accurately reflect the AD patient pool seeing 
as many elderly patients present with comorbidities. Because of this it is likely that many 
AD patients would be taking prescription pharmaceuticals to help counteract those 
conditions as well. Therefore polypharmacy and drug-drug interactions are certainly a 
cause for concern in elderly AD patients. It is also interesting to note that donepezil and 
rivastigmine are approved for all severities of AD, whereas memantine is usually used 
only in moderate to severe stages of the disease (Khoury, 2018). Interestingly, clinical 
trials attempting to identify any correlation between APOE4 status and cholinesterase 
inhibitor efficacy have been inconclusive. A recent meta-analysis by Waring and 
colleagues concluded that no significant difference exists between treatment efficacy and 
reaction in APOE4 non-carriers versus either APOE4 heterozygotes or homozygotes 
(Waring, 2015).  
As evidenced by an approved drug combination, the idea of combining one of the 
cholinesterase inhibitors and memantine has been a large area of research over the last 
few years and the results are mixed depending on the cholinesterase inhibitor used. 
Studies have shown improved clinical effects and an easier drug regimen resulting in 
potentially greater adherence for the combination of memantine and donepezil, however, 
a study that evaluated the concomitant consumption of galantamine and memantine found 
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contrasting results (Boinpally, 2015; Chen, 2017; Hager, 2016) in that memantine use 
erased many of the beneficial effects of galantamine over placebo. Therefore, the concept 
of combining memantine and a cholinesterase inhibitor is not necessarily always best 
clinical practice and more research may be needed in the area. Based on the research, it 
may also be a wiser choice to select combination therapy with donepezil rather than other 
cholinesterase inhibitors both because of the ease of already existing combinations and 
that research has at least shown some support for improved benefits of the combination of 
donepezil with memantine, whereas results have not been as robust when combined with 
the other two approved cholinesterase inhibiting drugs.  
Evidence for the benefit of combination therapy with donepezil and memantine is 
provided by an analysis performed by Chen and colleagues where they analyzed 11 
English and non-English studies exploring donepezil treatment alone versus in 
combination with memantine (Chen, 2017). These studies were found after scouring 
several large publication databases (Pubmed, Medline, Embase, PsycINFO, and 
Cochrane) and eliminating any duplicate studies. All of the studies reviewed were 
performed in human subjects who had been diagnosed with AD. Their analysis found a 
significant improvement in cognitive function of those patients that had been randomized 
to combination therapy over donepezil administration alone (Chen, 2017). The effect size 
of this difference was found to be moderate, a Hedges’ g, a measure of effect size similar 
to Cohen’s d, of 0.378. This significant improvement survived secondary tests for 
heterogeneity and the authors also failed to find any evidence of publication bias in the 
articles they evaluated for their analysis. The authors also found a moderate effect size 
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for a significant decrease in behavioral and psychotic symptoms of dementia (BPSD), 
though this finding may need to be taken cautiously seeing as evidence of publication 
bias was also reported for BPSD although no such bias was detected for their analyses on 
cognitive function. (Chen, 2017). A significant improvement in global functions, Hedges 
g of -0.585, was also found again showing that memantine/donepezil combination 
therapy exceeded standard donepezil treatment alone for patients of moderate to severe 
AD (Chen, 2017). Finally, no significant differences were found in adverse effects (AEs) 
for the two treatment groups, the largest category of reported AEs was gastrointestinal, 
which is not surprising seeing as GI effects are commonly reported with cholinesterase 
inhibition treatment, followed by mental side effects (Chen, 2017). The authors also 
found no difference in the approach to medical administration between the studies 
reviewed. The analysis by Chen provides moderate support for the notion that 
combination treatment is at least somewhat more beneficial than donepezil treatment 
alone and that this benefit comes without any added risk or increase in adverse side 
effects (Chen, 2017).  
Boinpally investigated whether administering two separate doses of donepezil and 
memantine proved more effective than the approved combination pharmaceutical and 
also if administering food with the prescription affected the pharmacokinetics of the 
combination pill. It was also explored whether the combination medication could be 
opened and sprinkled onto an easy to swallow food, in this case applesauce, in order to 
administer to patients who may be suffering from dysphagia, a difficulty or inability to 
swallow. They examined data from two phase I trials and found that the value of time to 
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max concentration (t-max) for the two administration protocols (dual administration or a 
combination pill) did not differ significantly (Boinpally, 2015). Though the t-max for co-
administration was fourteen hours and the combination pill was twenty-four hours. 
Furthermore differences between maximum concentration and area under curve, a 
measure of bioavailability, were not significant signaling that the bioavailability of both 
preparations is similar and equivalent. The proportion of adverse effects from both 
treatments did not differ significantly and both procedures resulted in similar adverse 
effects, mainly GI and mental distress (nausea, vomiting, dizziness, headache) 
(Boinpally, 2015). The second phase I trial they investigated looked at whether taking the 
medications after fasting or after a high-fat diet altered the pharmacokinetics as well as 
whether administering the contents of the approved combination medication over 
applesauce after a period of fasting had an effect on the bioavailability of the medicine. 
The study found that median t-max time for memantine, 14 hours, was significantly 
shorter for intact pill with a high fat meal or the contents sprinkled on applesauce rather 
than taking the intact pill on a fasting condition, which had a median time max of 24 
hours (Boinpally, 2015). However, the maximum concentration and area under curve 
profiles for all three administration protocols were similar. There was a slightly higher 
rate of treatment adverse effects for the contents sprinkled on applesauce condition, 
however it is important to note that this study was conducted in healthy younger 
individuals and did not include a titration phase, therefore GI adverse effects may be due 
to a lack of titration phase. It is also important to remember that these subjects had no 
experience with donepezil or memantine, whereas many of the subjects in studies that 
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utilized AD patients may have taken similar medications before. Oftentimes AD drug 
studies include titration phases where the dosage of the medication is gradually increased 
in an effort to allow for greater tolerance (Boinpally, 2015) though this was not the case 
in the Boinpally study. Though both of the analyzed trials took place in healthy non-AD 
afflicted volunteer subjects the findings that all three routes of administration have 
similar bioavailabilities, even if time to max concentrations may differ, is a comforting 
one and provides evidence that caregivers could administer memantine and donepezil to 
their AD patients as either two separate pills or one combined pill with similar efficacy 
(Boinpally, 2015). The ability to administer the contents of the pill safely and effectively 
when mixed in with softer and easier to swallow food is also an important practical 
advantage to the combination medication seeing as many AD patients may have physical 
difficulty swallowing several pills or eating larger or tougher to chew and swallow meals. 
Additionally, it provides both paid and non-paid caregivers with an easier alternative and 
may save both time and frustration when caring for their friends and family.  
Therefore, the above studies show that at least when the cholinesterase inhibitor 
of choice is donepezil dual therapy with memantine, both as separate pharmaceuticals or 
as a combination pill is safe and effective.  
Chase and colleagues attempted to address the issue of tolerability of 
cholinesterase inhibitors limiting the doses that are often prescribed to only around 25 or 
30% inhibition of cortical cholinesterase activity achieved with the standard doses of 5 or 
10 mg/day of donepezil (Chase, 2017). Therefore, they posited that co-administering a 
peripheral anticholinergic, in an effort to make higher doses of the active prescription, 
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donepezil, tolerable and therefore provide proof of mechanism of a way to attempt to 
increase the plasma concentrations of an approved AD medication. If plasma 
concentrations of donepezil could be increased it would offer greater symptom relief and 
perhaps a longer duration of effectiveness for patients. The peripheral anticholinergic 
they chose was Solifenacin, or CPC-201. Their study consisted of four stages; baseline, 
solifenacin titration, donepezil titration, and finally maximum tolerable dose 
maintenance. All subjects were able to tolerate solifenacin administration and titration, 
which led up to a daily active dose of 15 mg/day and solifenacin administration was 
found to have no significant adverse effects or detrimental effects on cognitive measures 
or other markers of AD and its symptoms (Chase, 2017). Once solifenacin had been 
titrated up to 15 mg/day, donepezil was titrated up from a starting point of 10 mg/day by 
incremental increases of 5 mg/week up to 25 mg/day and then afterwards by 5 mg 
increases every two weeks up to either the maximum protocol approved dosage of 40 
mg/day or until the patient found the dosage to be intolerable, at which point the last 
tolerated dosage was taken to be the maximum tolerated dose (MTD). All of the patients 
included in their study, albeit a small sample size of 34 patients, were able to tolerate up 
to the 25 mg/day dosage and 88% of the patients were able to tolerate the maximum 
provided dosage of 40 mg/day (Chase, 2017). In the patients that had a MTD below 40 
mg/day plasma concentrations of donepezil were similar to those of patients who had 
tolerated 40 mg/day suggesting that effective levels of the drug were similar for all 
patients. The authors reported a mean plasma donepezil concentration of 258 ng/mL, 
ranging from 104 to 420 ng/mL. This reflected a 4.5 fold increase in plasma donepezil 
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over mean plasma concentrations of donepezil at baseline, which was after three months 
of 10 mg/day donepezil treatment (Chase, 2017). The mean baseline donepezil 
concentration was reported as 57 ng/ml. This study also showed that cholinesterase 
inhibitor treatment could be drastically improved if co-administration of a peripheral 
anticholinergic was added to the patient’s pill load, or if a combined pharmaceutical 
could be developed (Chase, 2017). If the findings of Chase et. al. could be expanded and 
shown to be replicated in a larger and more diverse patient pool it would potentially mean 
that AD treatment could become more aggressive and prolonged over the current 
standard of care without the need to wait for a novel compound to pass FDA approval. 
The greater plasma concentrations of donepezil also correlated to a greater cognitive 
benefit as evidenced by a 2.5 point increase on average on the cognitive subset of the 
Alzheimer's Disease Assessment Scale (ADAS-Cog) (Chase, 2017). This improvement 
peaked at week 18 after stable dose concentration of donepezil was achieved and then 
showed a similar rate of drop-off in efficacy as suffered by the standard 10 mg/day 
dosing regimen of donepezil, albeit from a larger starting point (Chase, 2017). This 
finding that the rate of drop-off in efficacy is similar to the current dose 
pharmacokinetics, and the fact that the decrease begins at a higher point are the 
background for the claim that solifenacin co-administration could prolong the usefulness 
of cholinesterase inhibitors such as donepezil. The ability to raise the maximum tolerated 
dose of donepezil via solifenacin co-administration also had a statistically significant 
effect on global function, as measured by the CGI, and a significant increase in CGI 
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score, with the combined score (investigator and caregiver) increasing by an average of 
0.94 points (Chase, 2017).  
 A second general concern with the pre-approved pharmaceuticals for AD is that 
their clinical benefit may be short lived and may last only one year or perhaps two. Hager 
and colleagues’ review of randomized double-blind clinical trials in Europe found that 
galantamine had beneficial effects in patients even after two years of adherence, which is 
a longer duration than many other clinical trials, because most drug trials typically run 
from six to twelve months (Hager, 2016). These findings could be used alongside the 
findings of Chase and colleagues to help build a case for prolonged cholinesterase 
treatment, and perhaps seeing if solifenacin use could produce similar increases in 
tolerable dosage and perhaps duration of effective treatment in Galantamine users as it 
did in a small sample of donepezil users. Furthermore, the ability to extend and better the 
standard of care for Galantamine would be exceptionally important for these patients, due 
to the fact that Hager and colleagues also found that Memantine co-administration may 
not be beneficial in Galantamine patients and therefore these patients may already be 
deprived of the option to pursue NMDA and cholinesterase co-administration or 
compound drugs, another common method of providing better clinical outcomes (Hager, 
2016).  
 Rivastigmine is the third of the cholinesterase inhibitors that has been approved 
for symptom management in AD. Rivastigmine is not metabolized by the CYP450 
enzyme system in the liver, as donepezil and Galantamine are, and therefore offers fewer 
potential drug-drug interactions and also a chance at lower hepatic toxicity and perhaps 
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better bioavailability (Khoury, 2018). One downside of Rivastigmine is that it has been 
associated with and found to have the highest incidence of adverse effects, which could 
reduce its tolerability for patients. However, Rivastigmine is also the only cholinesterase 
inhibitor that is available in a non-oral formulation and can be administered via 
transdermal patch (Khoury, 2018). Khoury set out to explore whether the rivastigmine 
transdermal patch was capable of achieving the same plasma concentrations of drug as 
the oral pills. In addition, Khoury was curious if the incidence and severity of adverse 
side effects is reduced by use of a transdermal patch. Finally Khoury investigated 
whether the patch could allow for a slower and more controlled administration of the 
medication than a simple oral administration does. The transdermal patch is found to 
release around 50% of the loading dose over a 24-hour period and patches have been able 
to be produced and manufactured to allow for similar plasma concentrations as any 
currently available pill dosage (Khoury, 2018). For example the 4.6 mg patch has been 
shown to achieve similar concentrations of the drug to the 6 mg oral dose, and the 9.5 mg 
patch has been shown to be equivalent in efficacy and plasma concentration to the 12 mg 
maximally recommended oral dose. Additionally the transdermal patch has been 
approved in a 27 mg administration, which releases 13.3 mg over a twenty four duration 
in an effort to help treat patients that have progressed to severe AD (Khoury, 2018).  The 
rivastigmine transdermal patch was associated with local dermatologic adverse effects 
including itching and mild inflammation due to irritant contact dermatitis. However, 
these effects can be alleviated by use of a topical corticosteroid on the application site as 
well as by occasionally changing the site of patch placement in order to prevent one 
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specific area of skin from becoming too irritated (Khoury, 2018). The most serious safety 
concern regarding the transdermal patch is the potential to overdose if two patches are 
placed on a patient simultaneously. This is due to the fact that the patch is intended to be 
changed daily and that if a patch is left on for more than twenty-four hours it will 
continue to release the rest of its loaded dosage into the bloodstream, seeing as only 50% 
of the dose is released over the intended twenty four period (Khoury, 2018). Therefore, 
the addition of a second patch without the removal of the previous one will result in 
dramatically higher drug concentrations and toxicity associated with carbamate toxicity, 
which is defined by hypersalivation, miosis, and bronchorrhea, as well as potential 
dehydration and renal failure or damage from excessive vomiting or diarrhea (Khoury, 
2018).  The transdermal patch also did not have differences from the 12 mg/day oral dose 
on electrocardiogram (ECG) or other measures of cardiovascular health. The above 
studies show that the transdermal patch is a safe alternative to oral medication for patients 
with dysphagia or who have trouble remembering to take oral medications. Rivastigmine 
also has a lower chance of negative effects of polypharmacy seeing as it has reduced 
drug-drug interactions as compared with donepezil and galantamine and the application 
of a transdermal patch may be more easily managed by caretakers provided they 
remember to never have two patches placed at the same time to avoid overdosing and are 
vigilant about providing necessary care for any dermatological adverse side effects 
(Khoury, 2018).  
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DISCUSSION 
Now that the literature on the leading hypotheses for AD progression, genotype 
effects, lifestyle factors, and currently approved medications has been reviewed, the 
hurdles and flaws in research efforts and finding effective pharmaceutical interventions 
for AD patients will be discussed. One of the major hurdles affecting research efforts and 
making it hard to improve the clinical care of Alzheimer’s is that symptoms generally do 
not present until after decades of plaque and tangle buildup and accumulation, meaning 
that by the time symptoms present it may be too late to stop or reverse the effects of the 
disease. In these cases, the best physicians and family members can hope for is to slow 
the progression of the disease because there is still no drug or compound which is able to 
either stop amyloid buildup safely or cure AD. Due to the fear that by the time patients 
enroll in clinical trials or seek medical help it may be too late to provide significant aid, 
much effort and research has focused on finding a way of diagnosing patients at risk for 
developing AD or who are already showing signs of plaque build-up before symptom 
presentation. This could be done using Pittsburgh Compound B Position Emission 
Tomography (Pib-PET) imaging for amyloid imaging and 18F scans for tau buildup. Two 
major areas of research into earlier diagnosis have been focused on efforts to identify a 
reliable and useful blood or cerebrospinal fluid biomarker, and brain imaging techniques, 
specifically Fluorodeoxyglucose position emission tomography (FDG)-PET and Pib-
PET. FDG-PET scans can be used to measure glucose uptake and therefore metabolic 
activity in certain areas of the brain. This may provide a tool to help better understand 
brain atrophy and damage and where it may be occurring in a patient. Pib-PET is a tool 
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that is often used to better map and view the extent of amyloid deposition that has already 
occurred in a patient’s brain (Byun, 2017). Although these techniques are incredibly 
informative they are also very expensive and time-consuming for researchers, clinicians 
and patients. If a reliable blood or CSF biomarker could be found it would make it more 
cost-effective for patients because physicians could recommend imaging only to those 
patients who’s biomarkers show cause for concern. Many of the proposed markers are 
proteins discussed above such as serum and blood levels of Aβ40 and Aβ42, total tau, 
and phosphorylated tau. However, these proteins are not always informative of the 
mechanisms and pathways by which AD develops. This is why many prospective cohort 
studies are trying to include neuroimaging for as many of their subjects as possible. 
(Byun, 2017; Johnson, 2017). A third area of concern in designing effective studies on 
AD is that many of the psychometric and behavioral batteries that are employed to test 
cognitive function and decline such as the mini-mental state examination (MMSE) and 
the cognitive arm of the AD battery may not be very specific or may be subject to floor 
and ceiling effects meaning that they may not be the best tool for subject selection in 
future AD studies.   
It is also important to note that much of the research into AD has been down in 
elderly populations or populations that have already become symptomatic. Many of the 
highlighted articles have brought up the need for research into younger age cohorts, such 
as middle aged participants, in order to better differentiate subtle and sensitive changes in 
tau formation, amyloid deposition. Unfortunately, it may also be prudent to go back and 
re-evaluate relationships and risk factors that have been found to have little effect on the 
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development of AD seeing as it may’ve been unable to detect smaller changes in a 
population where neurodegenerative damage had already happened to a large extent, the 
same may be true of rescuing performance on several indicators of memory or cognitive 
ability. In terms of other important research considerations for future studies it’s also 
important to acknowledge that many of the cognitive measures used in AD research may 
have floor or ceiling effects and only using one or two measures may not paint a holistic 
and full picture of a patient’s symptoms or cognitive declines (or lack thereof). Therefore, 
it may be best practice to combine a mixture of cognitive based evaluations, brain 
scanning, and other outcome measures so that each study is getting closer to the true 
picture of AD in their populations. An idea that could help alleviate this problem is 
researchers agreeing on a generally accepted battery of outcome measures. Obviously 
some measures would have to be included or excluded from specific studies in order to 
better examine their specific study aims. Though there is a downside to this approach in 
missing evidence from some analyses, a standard battery would allow for the benefit of 
more confident comparison of results across studies. This increased confidence and 
clarity would make it easier to better elucidate which independent factors hold more 
promise for future AD research than others. In fact Byun and colleagues have developed 
a prospective cohort of Korean subjects, classified as young and cognitively normal, 
elderly and cognitively normal, mild cognitive impairment, or AD diagnosis to better 
understand which biomarkers or imaging scans are most effective (Byun 2017) . This 
Korean cohort could be very useful in determining key steps in the progression of AD. 
Additionally this cohort could provide insight into thresholds, at which to begin 
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intervention or more regular screening in an effort to help guide clinicians on a patient’s 
personal disease course.  
However, one interesting and important detail to note is that the studies collected 
here were performed in a relatively wide variety of geographic locations spanning from 
Australia, to western Europe, the United States of America, and middle eastern countries 
such as Turkey. Therefore, this continues to demonstrate the fact that AD is becoming a 
global phenomenon and public health issue, and not one that is simply confined to a 
number of countries or exclusively wealthy nations. It also underlines that the hallmarks 
of AD are similar in all societies and that AD does seem to be a truly universal affliction 
and one that would be sensible to direct not only local or national funds towards, but also 
global health funds due to the large scope of the condition.  
Many of the studies reviewed in this analysis share common design flaws or could 
be improved in similar ways. Firstly, most of the studies used patient populations that 
were already elderly and therefore prospective cohort studies are more difficult to 
organize, and there may be limited ability to see real changes if study control populations 
are already afflicted by neurodegeneration, just to a lesser extent than the active groups. 
Also many of the studies conducted on data from large AD cohorts do not include more 
than two time points, initial and one follow up. This is curious seeing as when 
researching a chronic condition such as Alzheimer’s multiple follow-ups should be 
recommended because it allows physicians or researchers to see if changes might occur 
after a certain duration, and also if any improvements are being made. 
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This paper has tried to demonstrate that two areas of AD, which are sometimes 
forgotten about in Alzheimer’s debates, both lifestyle factors and current medication may 
be useful tools in helping the public better understand how to minimize their risk of AD 
at the moment and perhaps how to better manage symptoms of patients who are already 
suffering from AD. Many of the studies also brought up modifiable risk factors such as 
dietary intake, alcohol use, and the importance of physical activity and exercise (Johnson, 
2017; Nagga, 2018; Schwarzinger, 2018). Therefore, these modifiable and easy to 
understand risk factors could be disseminated to the public as part of public service 
announcement and are further evidence for the importance of non-for-profit initiatives to 
popularize and support regular exercise and overall a healthy lifestyle. These programs 
would help people build the best cardiovascular and metabolic profile that each person 
could have. In fact with a lack of revolutionary and curative compounds and the 
inevitable reality that the next generation of AD drugs may be a few years away due to 
the structure and time consuming nature of FDA trials, these modifiable lifestyle risk 
factors may be one of our strongest tools and an individual’s best weapon in the fight 
against dementia in general and AD. The Western diet and the diet of an average 
American has become saturated with unhealthy norms and choices, and although 
healthier diet choices will not definitively prevent AD, evidence suggests that it could 
have a significant effect. Diet modification is also something that each person is capable 
of doing. Such changes would also reduce the risk of several comorbid conditions with 
AD such as vascular distress, type II diabetes, and this can only help to improve the 
overall well-being of a patient as well. However, it is also vital that physicians and 
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clinicians continue to screen and assess levels of key dietary nutrients, such as EPA and 
DHA in a patient’s blood or CSF because as patients age there may be a need to increase 
the levels of these species in order to help better repair and protect lipid membranes and 
ward off worsening neurological damage. This concern was addressed by the LipiDiDiet 
study and although they found some mild support for the benefits of the supplement, both 
Souvenaid and similar dietary supplements should be further investigated since they 
would provide a relatively inexpensive, easy, and very accessible way to treat AD. This 
again helps to illustrate the importance of prospective and long-term studies when 
studying a slow and degenerative disease such as late-onset AD.  
 It would also be beneficial to see if the usage of a dietary supplement, such as 
Souvenaid, and one of the existing FDA approved medications for AD were able to better 
improve cognitive performance when used in combination or even slow any further 
neurological or cognitive deterioration. If a study did find any benefit of using the two 
sources in combination than this would allow for an improved clinical plan.  
 There are also a number of lifestyle choices and preventative measures that people 
can take upon themselves to instigate long before the hallmark damage of AD and other 
neurodegenerative disease has set in in order to better protect themselves from these 
conditions. For example, vitamins C, B6, B12, and E have all been shown to be helpful in 
preventing the neurological changes and damage associated with AD and so it would be 
advised that patients take a multivitamin containing these vitamins, or start up a vitamin 
regimen if they are particularly worried about AD or other dementia related disorders 
(Cansev, 2017; de Wilde, 2017: Soininen, 2017). There is also some evidence pointing to 
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the fact that mitochondrial distress might be contributing to AD. If this is the case it is 
logical to believe that glucose metabolism and the glucose energy state of the brain may 
be reduced. This could also possible further contribute to increased mitochondrial 
demand and subsequent pathology, or that the reparative mechanisms that the brain is 
trying to employ require a greater glucose load in order to “bankroll” these rebuilding 
processes (Jan, 2017). If this is the case then further research should be conducted to see 
if adding glucose (or perhaps more complex sugars such as fructose or galactose) to 
dietary supplements aimed at AD may increase their effectiveness and help to reduce 
brain damage. Generally increased simple carbohydrates and sugars in diets is frowned 
upon and seen as unhealthy, but seeing as AD primarily affects an older population in 
which concerns of the onset of conditions such as diabetes or significant weight gain is a 
lesser concern when compared with the benefits of avoiding neurological damage and 
AD, the risk-benefit may well be worth it in this case.  
 All of the above highlighted research on the effects of diet and vitamin intake 
could also be used as grounds to fund a long-term prospective study, ideally in a large 
and diverse subject pool, to better understand the beneficial potential that these 
interventions and lifestyle changes could truly make. Indeed the evidence from Cansev 
and colleagues shows the importance of taking both necessary fatty acids and 
antioxidants and the fact that these two categories of dietary supplements may act in a 
synergistic fashion (Cansev, 2017). Obviously long-term prospective studies are 
extremely expensive and unlikely to come to fruition or be funded without strong 
rationale, but so far this paper has shown that there is previous research based evidence to 
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show that these sort of interventions could have a significant impact on neurological 
health. It is for this reason and the goal of preventing or slowing the neuropathological 
hallmarks of Alzheimer’s disease that makes up the rationale for an expensive study. AD 
is a condition that affects tens of millions of people worldwide and therefore is definitely 
a cause worthy of investing significant resources into. Also prospective studies would be 
needed in order to better evidence that these interventions can have a clear benefit on AD 
and would be ethical to perform before medical associations and professionals start to 
recommend certain diets, supplements, or vitamin intakes as being protective against AD. 
This studies are also necessary because clearly physicians would not want to ascribe 
certain effects or benefits to substances without having very strong research to support 
those claims.  
Research on the five currently approved medications for AD shows that there are 
potentially ways to either extend usefulness of cholinesterase inhibitors or more easily 
managed routes of administration, but this does not change the fact that there is still no 
curative medication for AD (Boinpally, 2015; Chase, 2017). The current aim of clinicians 
should be working with patients to try and delay and slow the progression of the disease 
and the severity of neurodegeneration if at all possible through the use of modifiable risk 
factors and vigilant monitoring for the start of the disease course. Clinicians should also 
consider incorporating imaging scans of patients into their standard of care once patients 
reach a certain age if at all possible and feasible due to the expensive nature of medical 
imaging. If imaging cannot be easily obtained and utilized than clinicians would be 
advised to look to plasma or CSF biomarkers as any indication of potential 
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neurodegeneration and if the results of these tests provide cause for concern than it would 
provide added cause for the patient to seek out and invest in imagining to allow their 
medical team a better insight into their neurological health.  
 The studies we have reviewed have also posed that certain already approved 
medications such as warfarin or non-vitamin K depleting anticoagulants could be 
prescribed off label to help patients with dementia, including AD (Gonzalez-Reyes, 
2017). Though these medications certainly won’t be as effective as novel therapeutics 
targeted at various sources of AD, they will provide an expanded options list for 
physicians as we wait for pharmaceutical companies and research labs to identify new 
therapeutic species and compounds and then wait for these compounds to successfully 
pass FDA trials.  
 If pharmaceutical companies want to continue using the amyloid hypothesis as the 
underlying rationale for new drugs than a promising area of potential is compounds that 
could target neuroinflammation and perhaps the feed-forward loop between astrocytes, 
inflammatory cytokines, and amyloid synthesis and deposition. The most likely targets in 
these pathways would be the proinflammatory cytokines seeing as a drug that targets 
astrocytes would likely be dangerous due to the fact that astrocytes are part of the brain’s 
natural defense and so a drug would want to target astrocyte’s damaging interactions 
without knocking out astrocyte activity completely. Developing drugs with targets in the 
brain is quite difficult though because a compound must be able to pass the blood brain 
barrier. However, if a drug could be developed to help reduce neuroinflammation that 
would greatly help not only AD patients, but dementia patients in general and would 
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most likely be able to be used in concert with an anticoagulant or vascular drug to further 
help reduce the risk of vascular dementia or hypoperfusion of the brain. There might be 
some risk involved with lowering the body’s ability to react to insult or physical injury by 
tampering with inflammatory pathways, but if it truly could bring about a significant 
slowing or reduction of AD pathology than the reward and benefit may outweigh the 
potential risk. It should also be remembered that according to the amyloid hypothesis the 
aggregation of amyloid tangles is what causes the hyper-phosphorylation of tau and the 
neurofibrillary p-tau. Another potential target of novel therapeutics could be glial 
maturation factor (GMF), seeing as the authors of the GMF study, hypothesized that 
GMF signaling may be done in an autocrine or paracrine fashion. This means that the 
effect of GMF may be propagated and therefore a drug could be used to dampen this 
effect without entirely eliminating GMF signaling. In this way a drug targeting GMF 
would have less of a chance damaging healthy interactions and cells.   
 A more specific target for drug development might be the Major Facilitator 
Superfamily Domain Containing 2A (MFSD2a), a membrane transport protein that plays 
roles in both blood-brain barrier integrity and DHA uptake. The reasons for selecting this 
protein as a target are that it is implicated in the mechanism by which APOE4 genotype 
may have decreased blood-brain barrier integrity, and it should be remembered that a 
high percentage of AD patients are APOE4 carriers, making this a lucrative and logical 
subject population. A second reason is that if DHA uptake can be increased in APOE4 
carriers or non-carriers alike than the effectiveness of easy and cost-effective strategies, 
such as dietary intake of omega-3-fatty acids and antioxidants and vitamins increases and 
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this makes lowering the risk of this disease a more easily obtained goal for many people 
that may not be able to afford expensive novel medication indefinitely. Additionally, 
preserving the integrity of the blood-brain barrier is essential for brain health outside of 
any effects it may have on DHA metabolism.  
 One of the most important takeaways of the varied literature reviewed in this 
paper is that there are several possible causes of AD and several possible pathways that 
can cause further neurological damage and contribute to the disease and symptom 
progression. Therefore, it is very possible that patients may require different medications 
and dosages based on what pathway or causal factor seems to be driving their individual 
case of AD. For example, a patient that is shown to suffer from amyloid burden far more 
than a patient suffering from tauopathy or neurotoxic inflammation may be placed on 
different drugs or differing drug cocktails or dosages to best help combat their personal 
case of AD. This approach would also be in-line with the idea of personalized and 
individualized medicine, which is an important and growing force and idea in medicine 
and one that helps to keep care patient-centric. The development of drugs targeted at 
different AD related pathways and causes would also allow for better drug adherence and 
a simpler pharmaceutical program for patients making it easier to routinely follow their 
prescribed regimen. Another benefit of developing pharmaceuticals targeting different 
causes and pathways in AD and using these novel compounds in combination for patients 
is that many of the targets and species put forward in this paper, such as enzymes 
involved in inflammatory pathways or cytokines, may play important and healthy 
physiological roles as well. But, in AD it is an imbalance of them that is causing their 
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effects to turn toxic, therefore it is likely that many of the novel compounds developed 
will only aim to achieve a partial knockdown or reduction of the damaging effects, but 
may not be able to stop that pathway entirely due to fear of drug complications becoming 
more damaging than the conditions they are trying to stop. However, a drug regimen that 
works to target multiple pathways and sources of neurodegeneration and AD pathology 
will help to slow more than just one pathway and therefore would be useful in slowing 
the overall progression to AD and if effective enough may even be able to prevent 
symptom onset entirely. This concept of understanding that multiple pathways might be 
at work and the same species, or similar species, may be spurring on different 
mechanisms is essential to having a full picture of AD. For example, the article by Gunn 
and colleagues presents how pyroglutamate modified Aβ42 may be a seed for neuro-
fibrillation and may also be neurotoxic due to causing an influx of calcium into afflicted 
neurons, but may actually decrease the production of reactive oxygen species (Gunn, 
2016). Though this definitely is not a compound that could be used as a therapeutic for 
AD, it is beneficial knowledge seeing as lowering the modified Aβ42 may be a primary 
goal of very early treatment. This could be done in an effort to slow down amyloidosis 
whereas later in the disease course it may be more pertinent to employ methods targeting 
neuroinflammation and trying to repair neuronal membranes rather than simply slow 
amyloid deposition because amyloid deposition may already have reached a threshold 
where it cannot be completely reversed.  
 The concept of trying to make any necessary pharmaceutical interventions 
tolerable and easy to adhere to is especially important with neurodegenerative diseases 
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such as Alzheimer’s seeing as patients are already suffering from memory loss and loss 
of cognition and so overly complicated drug regimens will be hard for these patients to 
follow. This may lead to lower adherence and subsequently be less efficacious due to 
confusion and forgetting to follow the procedures or frustration by patients. If patients are 
no longer able to follow the directions and therefore lose interest in taking the drugs 
because it could cause them to feel overwhelmed by the demands of their prescription 
regimen. A counterpoint to this would be that many AD patients have caretakers, either 
family members or professional help, that ensure their adherence to drug regimens, but 
making the prescription load simpler and easier to take and adhere to will also help 
caretakers to remember. There is also an added benefit to the idea of a dietary supplement 
as oftentimes these supplements come in larger containers, and therefore may be easier to 
remember to take. They  may also carry less social stigma than taking pills or medication 
as there are several dietary supplements for a wide variety of conditions and dietary 
supplements can easily be disguised by placing them in water or in a branded container. 
 The most difficult hurdle to slowing AD progression and lessening the 
tremendous burden that this disease places on patients, families, and medical systems 
may lie in starting treatment in patients before the onset of symptoms. If this is the case, 
then physicians and their patients will have to come to a consensus on a reasonable time 
to start screening more frequently for AD and start preventative treatment if necessary. In 
terms of protocols and procedures for screening both imaging scans and plasma or CSF 
samples could be collected from patients regularly after they reach a certain age. This 
idea and system of screening at intervals has been used in trying to get ahead of a number 
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of diseases such as is the case in scheduled mammograms, or colonoscopies, in which 
patients routinely undergo screening for certain diseases after they pass a specific age 
threshold. In the case of AD periodic screens would be most effective every two or three 
years until evidence of amyloid buildup or tauopathy is seen and then screen frequency 
should increase to annually in order to monitor neurological progress. In many cases 
physician’s will likely base this decision on when imaging scans and blood or CSF work 
starts to show cause for concern. Physicians will also want to start to employ each 
patient’s genotype and genetic information into their decisions on when to start regular 
screening, prescribing medication, and also what forms of medication to prescribe. As 
such, AD treatment will certainly benefit from increasing the use of a patient’s genetic 
information in educating clinical decisions. Based on the evidence in this paper and the 
fact that late onset AD usually presents in the seventh or eighth decade of life it would be 
reasonable to start medication, if biomarkers and imaging provided evidence of AD 
progression, in a patient around sixty years of age because it would be most effective to 
start a pharmaceutical approach in the early stages of pathology. This would also limit 
neurological degeneration as opposed to starting treatment later in the course of the 
disease. However, certain dietary interventions such as proper intake of omega-3-fatty 
acids, antioxidants, and in general a healthier diet leading to lower triglycerides could be 
started at any point in life and the earlier these changes are implemented the better. Due 
to the nature of the disease and the fact that the prevalence of AD increases as one ages it 
is also likely that once a patient starts taking anti-AD medications they may be on them 
long-term or even indefinitely. Again though this is not an entirely new idea seeing as 
56 
 
many people remain on prescriptions long-term or even indefinitely for a number of 
conditions such as the use of insulin for diabetes or statin drugs for cholesterol control. 
Though this treatment courses are not ideal, longterm treatment might outweigh the risks 
of unchecked AD. Therefore the notion of taking a prescription daily indefinitely is not a 
novel one to the public and with a disease as widespread as AD there should hopefully be 
little stigma attached with someone taking daily medication to combat it, just like there is 
perceived to be little stigma associated with taking prescriptions such as Lipitor® 
(atorvastatin calcium) for cholesterol control.  
 Therefore a natural future research direction could be evaluating novel 
prescriptions in an animal cohort first, and then a younger cohort rather than using a 
sample of subjects who are already suffering from AD. As mentioned above a 
prospective study design would demonstrate if continued treatment with these 
compounds could help slow the progression of AD. If this was found to be the case than 
these drugs would be another tool that clinicians would be able to employ immediately 
with AD patients. Along the same line of thinking it would be helpful to investigate 
whether other anti-inflammatory compounds or drugs could be helpful in slowing the 
progression of AD or alleviating any of the cognitive symptoms.   
Conclusions 
 Medical researchers should continue to work towards better understanding how to 
potentially delay the pathology of AD as well as to continue to work with the five 
currently approved medications to better understand how to best utilize these drugs in 
order to give patients the maximum benefit possible. This would include further studies 
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on how co-administration of peripheral anticholinergic drugs, such as solifenacin, could 
be used with any of the three cholinesterase inhibitors, not just donepezil, as well as if 
there are any other ways to either enhance or extend the desired effects of these drugs. 
This work could also include further research into whether the drugs’ efficacy or 
bioavailability truly do decline significantly after a year of administration. Researchers 
would also want to investigate whether even if drug efficacy declines, are they still 
superior to no medication whatsoever, or would potentially switching cholinesterase 
inhibitors or switching to memantine or the combination of memantine and donepezil 
allow for a greater range of effective treatment.  
 On the industrial and commercial side of this equation large drug corporations 
would certainly be wise to continue pursuing curative measures for AD, seeing as the 
prevalence of the disease is only expected to increase with increasing longevities, an 
aging population, and more efficient medication being discovered to target various other 
conditions that affect elderly populations. However, there are definitely causes of 
neurodegeneration and pathways that lead to AD outside of the traditional amyloid 
hypothesis, and pharmaceutical companies might benefit from investigating compounds 
targeted at neuroinflammation, repairing neuronal membranes or improving the integrity 
of the blood brain barrier itself as being potentially effective in treating AD. 
Neuroinflammation may be a strong target for new pharmaceuticals as it has links to both 
neuronal death and membrane damage, as well as amyloid deposition. Another potential 
target for a compound that could be utilized early in the progression of the disease would 
be a drug that is aimed at reducing the pyroglutamate modification of Aβ42, since this 
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modified species is often implicated as a seeding agent for amyloid deposition, and is 
thought to be especially deleterious early in the neuropathology of AD.  
 Ultimately combined and creative efforts between physicians, pharmaceutical 
companies, medical researchers, and patients are needed to provide the best treatment 
courses and lifestyle modifications to reduce both AD risk and severity. In the more 
distant future hopefully medication will be developed that is aimed at halting or curing 
AD. This review and the research highlighted within it aims to shed light on the fact that 
there may not be one miracle drug for AD, but rather an arsenal of different compounds 
may be developed, each targeting a different pathway or mechanism of neurological 
damage. Additionally, this paper has shown that daily lifestyle modifications such as 
maintaining a regular exercise regimen, sleep schedule, healthy intake of omega-3-fatty 
acids and antioxidants, and seeking treatment for alcohol substance abuse disorders can 
help patients delay and lessen the severity of the neurological damage that is 
characteristic of AD. These efforts combined with earlier and more regular screening and 
the use of CSF, plasma, and neuroimaging techniques to monitor potential biomarkers of 
AD will hopefully give patients and clinicians a better treatment plan until novel curative 
therapeutics are found and approved.   
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